[A24-92] Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V
Last updated 16.12.2024
Project no.: A24-92
Commission: Commission awarded on 10.09.2024 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Reproductive health and birth
Indication:
Adult women of reproductive age with moderate to severe symptoms of uterine fibroids
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-92_en